- S笔记
-
At present,the foreign pharmaceutical enterprise Currently which entered in China has 1,500, the world"s top 20 multinational pharmaceutical enterprises have engaged in our joint venture, some also opened solely invested enterprise,the share of market of import medicine, joint venture medicine has more than 50%, this is one of the important reasons which it"s too wxpensive to see a doctor.
Foreign capital enterprise"s medicine, even exceed the patent period, the medicine price which Chinese enterprises manufactured with the same varieties is 41.3% than foreign capital enterprise"s price, some even just about 10% of a foreign-capital enterprise"s. And this is aimed at "separate pricing" product adjustment,it is expected to further adjust chinese-foreign medicine enterprises" balance.
Depreciating group after group at different times in future.
But the above domestic manufacturer"s views are not approved by foreign-capital enterprise.
Yesterday, a executives of China Association of Enterprises with Foreign Investment (CAEFI) drug research and development industry committee (RDPAC) indicate that Compared with international,our copy drug price is 22%~30% of international general price leve, which based on the original drug price adjustment would restain industry quality system input, against our country medicine market and the healthy development of the pharmaceutical industry.
For multinational pharmaceutical enterprise,due to a new drug of its r&d input is more than $1 billion basically, such a great investment need great number of expenses for medicine to give in return.
手工翻译,供参考!
- 苏萦
-
Currently entering the Chinese foreign pharmaceutical enterprise has 1,500 home, the world"s top 20 multinational pharmaceutical enterprises have engaged in our joint venture, some still opened solely invested enterprise, JinKouYao, joint venture medicine market share has more than 50%, this is causing a doctor expensive one of the important reasons.
Foreign capital enterprise medicine, even after a patent period, produced in China, Chinese enterprises manufacturing varieties with varieties of foreign capital enterprise price also just the price of drugs 40.13%, some even just about 10% of a foreign-capital enterprise. And this is aimed at "separate pricing" product adjustment, is expected to further adjust chinese-foreign medicine enterprises game balance.
Further price. Installment partial
But the domestic manufacturer views in a foreign-capital enterprise, not the approval.
Yesterday, China association of enterprises with foreign investment drug research and development industry committee (RDPAC listings) a executives in accepting our newspaper, said in an interview with the international comparison, producer prices in China for international generic-drug 22% of the general price level, with its ~ 30% price as a benchmark to adjust branded drug prices will restrain industry quality system input, against our country medicine market and the healthy development of the pharmaceutical industry.
For multinational pharmaceutical enterprise that, of a new drug because of its r&d input of more than $10 billion in basically, such a great investment need high expenses for medicine to give in return.
- 瑞瑞爱吃桃
-
At present,the foreign pharmaceutical enterprise Currently which entered in China has 1,500, the world"s top 20 multinational pharmaceutical enterprises have engaged in our joint venture, some also opened solely invested enterprise,the share of market of import medicine, joint venture medicine has more than 50%, this is one of the important reasons which it"s too wxpensive to see a doctor.
Foreign capital enterprise"s medicine, even exceed the patent period, the medicine price which Chinese enterprises manufactured with the same varieties is 41.3% than foreign capital enterprise"s price, some even just about 10% of a foreign-capital enterprise"s. And this is aimed at "separate pricing" product adjustment,it is expected to further adjust chinese-foreign medicine enterprises" balance.
Depreciating group after group at different times in future.
But the above domestic manufacturer"s views are not approved by foreign-capital enterprise.
Yesterday, a executives of China Association of Enterprises with Foreign Investment (CAEFI) drug research and development industry committee (RDPAC) indicate that Compared with international,our copy drug price is 22%~30% of international general price leve, which based on the original drug price adjustment would restain industry quality system input, against our country medicine market and the healthy development of the pharmaceutical industry.
For multinational pharmaceutical enterprise,due to a new drug of its r&d input is more than $1 billion basically, such a great investment need great number of expenses for medicine to give in return,
- 余辉
-
To date, 1500 foreign pharmaceutical companies have entered China. The world"s top 20 largest international pharmaceutical companies have already set up factories jointly with Chinese partners, and some of them have even established wholly owned subsidiaries. As a result, the amount of imported medicines and those produced by foreign-invested companies have accounted for more than a half of the drug market, which is a main contributor for the high cost of medical treatment.
Medicines produced by foreign companies, even off-patent ones, are sold at much higher prices than those produced by Chinese companies, while the pricing for the latter only accounts for 40.13% or, even as low as 10% of the former. The restructuring of medical pricing this time, focused on the products with "self-directed" prices, is supposed to rebalance a level playing field for both Chinese and foreign enterprises in the pharmaceutical industry.
Price will be cut step by step in batches in the coming period
The opinions from the domestic companies mentioned above have not been confirmed by their foreign-invested counterparts, though.
Compared with the global market, the exworks prices for Chinese generic medicines are 22%-30% of the overall international price level. It will constrain investment in the industrial quality system if we set the prevailing global prices as standards for regulating the price of indigenously-developed medicines, leading to some harmful effects to our domestic medical market and the sound development of our own pharmaceutical industry. For international pharmaceutical companies, the R&D investment for a new drug could easily exceed 1 billion dollars, a huge input that needs high price in return, said one senior executive from the R&D-based Pharmaceutical Association Committee of the China Association of Enterprises with Foreign Investment during the interview by our newspaper yesterday.